Congratulations to the teams at Palleon and Henlius, first patients dosed with B7H3-targeted sialidase immune therapy for ovarian cancer. Great partnership around glycan editing, an exciting new approach for immune modulation #glycotime
www.businesswire.com/news/home/20...
